Litcius/Paper detail

Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery

Cetin Sari, Richard L. Seip, Devika Umashanker

2021Frontiers in Endocrinology21 citationsDOIOpen Access PDF

Abstract

FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m 2 prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period.

Topics & Concepts

TopiramateMedicineMetforminBiguanideWeight lossType 2 diabetesDiabetes mellitusBody mass indexObesityCarbonic anhydrase inhibitorSurgeryMedical prescriptionInternal medicinePharmacologyEndocrinologyCarbonic anhydraseEpilepsyPsychiatryBiochemistryEnzymeChemistryPharmacology and Obesity TreatmentBariatric Surgery and OutcomesDiet and metabolism studies
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery | Litcius